MTOR and non-small cell lung carcinoma: Although some reports indicated that expression of mTOR/phosphorylated-mTOR (p-mTOR) has no significant association with prognosis in NSCLC patients [117], mTOR inhibitors including everolimus, temsirolimus, and ridaforolimus have been extensively applied in NSCLC patients in clinical trials.